Cardioprotective effects of dapagliflozin against the acute cardiotoxic effects of 5-fluorouracil

Background5-Fluorouracil (5-FU) has potential cardiotoxic effects, including direct cardiomyocyte damage, arrhythmia development, and coronary vasospasm. Numerous studies have demonstrated that dapagliflozin (DAPA) possesses cardioprotective properties. Theoretically, DAPA may have the potential to...

Full description

Saved in:
Bibliographic Details
Main Authors: Mehmet Hakan Uzun, Sebahat Ulusan, Afragül Yönet, Kadir Şeker, Murat Sevimli, Kanat Gülle, Adnan Karaibrahimoğlu, Aliye Kuyumcu, Selçuk Kanat, Mehmet Alagöz, Mevlüt Serdar Kuyumcu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2025.1633420/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849430361777373184
author Mehmet Hakan Uzun
Sebahat Ulusan
Afragül Yönet
Kadir Şeker
Murat Sevimli
Kanat Gülle
Adnan Karaibrahimoğlu
Aliye Kuyumcu
Selçuk Kanat
Mehmet Alagöz
Mevlüt Serdar Kuyumcu
author_facet Mehmet Hakan Uzun
Sebahat Ulusan
Afragül Yönet
Kadir Şeker
Murat Sevimli
Kanat Gülle
Adnan Karaibrahimoğlu
Aliye Kuyumcu
Selçuk Kanat
Mehmet Alagöz
Mevlüt Serdar Kuyumcu
author_sort Mehmet Hakan Uzun
collection DOAJ
description Background5-Fluorouracil (5-FU) has potential cardiotoxic effects, including direct cardiomyocyte damage, arrhythmia development, and coronary vasospasm. Numerous studies have demonstrated that dapagliflozin (DAPA) possesses cardioprotective properties. Theoretically, DAPA may have the potential to mitigate 5-FU-induced cardiotoxicity.Methods32 male Wistar albino rats were randomly divided into four groups of eight animals each: Control, DAPA, 5-FU, and 5-FU + DAPA. The 5-FU groups received a single intraperitoneal dose of 150 mg/kg 5-FU at the beginning of the study, while the DAPA groups were administered 10 mg/kg DAPA daily via oral gavage. Echocardiography, electrocardiography, and weight measurements were performed at baseline, and at the end of the first and second weeks. The experiment was concluded at the end of the second week, and tissue samples were collected for histopathological analysis.ResultsCompared to the 5-FU group, the 5-FU + DAPA group exhibited a 9.5% smaller reduction in ejection fraction, a 50% lower incidence of ST-segment elevation, and a 14.16% smaller increase in heart rate. Moreover, the prolongation of PR, QTc, and QRS durations was attenuated by 8.27%, 9.91%, and 34.5%, respectively (p < 0.05 for all). Histopathological analysis also revealed significantly reduced inflammation in the 5-FU + DAPA group (p < 0.05).ConclusionsDapagliflozin has shown to have cardioprotective effects against acute cardiotoxicity in a 5-FU-induced cardiomyopathy rat model.
format Article
id doaj-art-55b6485fcebb4078ad7cbe53f55dd80a
institution Kabale University
issn 2297-055X
language English
publishDate 2025-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cardiovascular Medicine
spelling doaj-art-55b6485fcebb4078ad7cbe53f55dd80a2025-08-20T03:28:01ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-07-011210.3389/fcvm.2025.16334201633420Cardioprotective effects of dapagliflozin against the acute cardiotoxic effects of 5-fluorouracilMehmet Hakan Uzun0Sebahat Ulusan1Afragül Yönet2Kadir Şeker3Murat Sevimli4Kanat Gülle5Adnan Karaibrahimoğlu6Aliye Kuyumcu7Selçuk Kanat8Mehmet Alagöz9Mevlüt Serdar Kuyumcu10Department of Cardiology, Republic of Türkiye Ministry of Health Kutahya City Hospital, Kutahya, TürkiyeDepartment of Histology and Embryology, Suleyman Demirel University Health Sciences Institution, Isparta, TürkiyeDepartment of Histology and Embryology, Suleyman Demirel University Faculty of Medicine, Isparta, TürkiyeDepartment of Cardiology, Suleyman Demirel University Faculty of Medicine, Isparta, TürkiyeDepartment of Histology and Embryology, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, TürkiyeDepartment of Histology and Embryology, Suleyman Demirel University Faculty of Medicine, Isparta, TürkiyeDepartment of Biostatistics and Medical Informatics, Suleyman Demirel University Faculty of Medicine, Isparta, TürkiyeDepartment of Nutrition and Dietetics, Suleyman Demirel University Faculty of Health Sciences, Isparta, TürkiyeCardiology and Cardiac Electrophysiology, Private Clinic, Bursa, TürkiyeDepartment of Surgery, Nassau University Medical Center, East Meadow, NY, United StatesDepartment of Cardiology, Suleyman Demirel University Faculty of Medicine, Isparta, TürkiyeBackground5-Fluorouracil (5-FU) has potential cardiotoxic effects, including direct cardiomyocyte damage, arrhythmia development, and coronary vasospasm. Numerous studies have demonstrated that dapagliflozin (DAPA) possesses cardioprotective properties. Theoretically, DAPA may have the potential to mitigate 5-FU-induced cardiotoxicity.Methods32 male Wistar albino rats were randomly divided into four groups of eight animals each: Control, DAPA, 5-FU, and 5-FU + DAPA. The 5-FU groups received a single intraperitoneal dose of 150 mg/kg 5-FU at the beginning of the study, while the DAPA groups were administered 10 mg/kg DAPA daily via oral gavage. Echocardiography, electrocardiography, and weight measurements were performed at baseline, and at the end of the first and second weeks. The experiment was concluded at the end of the second week, and tissue samples were collected for histopathological analysis.ResultsCompared to the 5-FU group, the 5-FU + DAPA group exhibited a 9.5% smaller reduction in ejection fraction, a 50% lower incidence of ST-segment elevation, and a 14.16% smaller increase in heart rate. Moreover, the prolongation of PR, QTc, and QRS durations was attenuated by 8.27%, 9.91%, and 34.5%, respectively (p < 0.05 for all). Histopathological analysis also revealed significantly reduced inflammation in the 5-FU + DAPA group (p < 0.05).ConclusionsDapagliflozin has shown to have cardioprotective effects against acute cardiotoxicity in a 5-FU-induced cardiomyopathy rat model.https://www.frontiersin.org/articles/10.3389/fcvm.2025.1633420/full5-fluorouracilcardiotoxicityheart failureSGLT2 inhibitorscardiomyopathy
spellingShingle Mehmet Hakan Uzun
Sebahat Ulusan
Afragül Yönet
Kadir Şeker
Murat Sevimli
Kanat Gülle
Adnan Karaibrahimoğlu
Aliye Kuyumcu
Selçuk Kanat
Mehmet Alagöz
Mevlüt Serdar Kuyumcu
Cardioprotective effects of dapagliflozin against the acute cardiotoxic effects of 5-fluorouracil
Frontiers in Cardiovascular Medicine
5-fluorouracil
cardiotoxicity
heart failure
SGLT2 inhibitors
cardiomyopathy
title Cardioprotective effects of dapagliflozin against the acute cardiotoxic effects of 5-fluorouracil
title_full Cardioprotective effects of dapagliflozin against the acute cardiotoxic effects of 5-fluorouracil
title_fullStr Cardioprotective effects of dapagliflozin against the acute cardiotoxic effects of 5-fluorouracil
title_full_unstemmed Cardioprotective effects of dapagliflozin against the acute cardiotoxic effects of 5-fluorouracil
title_short Cardioprotective effects of dapagliflozin against the acute cardiotoxic effects of 5-fluorouracil
title_sort cardioprotective effects of dapagliflozin against the acute cardiotoxic effects of 5 fluorouracil
topic 5-fluorouracil
cardiotoxicity
heart failure
SGLT2 inhibitors
cardiomyopathy
url https://www.frontiersin.org/articles/10.3389/fcvm.2025.1633420/full
work_keys_str_mv AT mehmethakanuzun cardioprotectiveeffectsofdapagliflozinagainsttheacutecardiotoxiceffectsof5fluorouracil
AT sebahatulusan cardioprotectiveeffectsofdapagliflozinagainsttheacutecardiotoxiceffectsof5fluorouracil
AT afragulyonet cardioprotectiveeffectsofdapagliflozinagainsttheacutecardiotoxiceffectsof5fluorouracil
AT kadirseker cardioprotectiveeffectsofdapagliflozinagainsttheacutecardiotoxiceffectsof5fluorouracil
AT muratsevimli cardioprotectiveeffectsofdapagliflozinagainsttheacutecardiotoxiceffectsof5fluorouracil
AT kanatgulle cardioprotectiveeffectsofdapagliflozinagainsttheacutecardiotoxiceffectsof5fluorouracil
AT adnankaraibrahimoglu cardioprotectiveeffectsofdapagliflozinagainsttheacutecardiotoxiceffectsof5fluorouracil
AT aliyekuyumcu cardioprotectiveeffectsofdapagliflozinagainsttheacutecardiotoxiceffectsof5fluorouracil
AT selcukkanat cardioprotectiveeffectsofdapagliflozinagainsttheacutecardiotoxiceffectsof5fluorouracil
AT mehmetalagoz cardioprotectiveeffectsofdapagliflozinagainsttheacutecardiotoxiceffectsof5fluorouracil
AT mevlutserdarkuyumcu cardioprotectiveeffectsofdapagliflozinagainsttheacutecardiotoxiceffectsof5fluorouracil